170868 ⎘
Detection or diagnosis of diseases; Cardiovascular disorders Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH ATRIAL FIBRILLATION AND/OR ATRIAL FLUTTER
#2EXPERIMENTAL METHOD FOR CLINICAL RESEARCH OF TARGETING MOLECULES BASED ON ATRIAL FIBRILLATION WARNING SYSTEM
#3METHOD FOR THE PROGNOSIS OF PATIENTS SUFFERING FROM ATRIAL FIBRILLATION
#4TREATMENT METHODS HAVING REDUCED DRUG-RELATED TOXICITY AND METHODS OF IDENTIFYING THE LIKELIHOOD OF PATIENT HARM FROM PRESCRIBED MEDICATIONS
#5CIRCULATING TOTAL-NT-PROBNP (GLYCOSYLATED AND UNGLYCOSYLATED NT-PROBNP) AND ITS RATIO WITH NT-PROBNP (UNGLYCOSYLATED NT-PROBNP) IN THE ASSESSMENT OF ATRIAL FIBRILLATION
#6RET (REARRANGED DURING TRANSFECTION) FOR THE ASSESSMENT OF STROKE
#7TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION
#8METHODS AND COMPOSITIONS FOR CARDIOVASCULAR DISEASE DETECTION AND MANAGEMENT
#9BIOMARKERS FOR THE DIAGNOSIS OF ATRIAL FIBRILLATION CAUSE OF STROKE
#10MARKERS FOR ATRIAL FIBRILLATION (AF)
#11CIRCULATING FGFBP-1 (FIBROBLAST GROWTH FACTOR-BINDING PRO-TEIN 1) IN THE ASSESSMENT OF ATRIAL FIBRILLATION AND FOR THE PREDICTION OF STROKE
#12COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING ARRHYTHMIAS
#13CIRCULATING SPON-1 (SPONDIN-1) IN THE ASSESSMENT OF ATRIAL FIBRILLATION
#14CIRCULATING BMP10 (BONE MORPHOGENIC PROTEIN 10) IN THE ASSESSMENT OF ATRIAL FIBRILLATION
#15CIRCULATING TFPI-2 (TISSUE FACTOR PATHWAY INHIBITOR 2) IN THE ASSESSMENT OF ATRIAL FIBRILLATION AND ANTICOAGULATION THERAPY
#16CIRCULATING DKK3 (DICKKOPF-RELATED PROTEIN 3) IN THE ASSESSMENT OF ATRIAL FIBRILLATION
#17Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications
#18METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH ATRIAL FIBRILLATION AND/OR ATRIAL FLUTTER
#19Nanovesicles derived from bacteria of genus and use thereof
#20Circulating Angiopoietin-2 (Ang-2) and insulin-like growth factor-binding protein 7 (IGFBP7) for the prediction of stroke
#21FATTY ACID BINDING PROTEIN 3 FOR THE ASSESSMENT OF ATRIAL FIBRILLATION (AF)
#22Methods for treating or predicting risk of a ventricular tachyarrhythmia event
#23Circulating Angiopoietin-2 (Ang-2) for the prediction of recurrence of atrial fibrillation
#24Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications
#25Compositions and methods for diagnosing and treating arrhythmias
#26SYSTEMS AND METHODS FOR MODELING DISEASE AND ASSESSING ADVERSE SIDE EFFECTS OF THERAPEUTICS THEREFOR
#27CIRCULATING ESM-1 (ENDOCAN) IN THE ASSESSMENT OF ATRIAL FIBRILLATION AND/OR STROKE
#28USE OF CD146 AS A MARKER OF THE VASCULAR WALL TENSION
#29Methods of detection and treatment for cardiovascular disease and foot wounds
#30Systems and methods for assessing data collected from an electrically active cell culture
#31System and methods for predicting drug-induced inotropic and pro-arrhythmia risk
#32Troponin and BNP based diagnosis of risk patients and cause of stroke
#33METHODS OF DETERMINING RISK OF CARDIAC ARRHYTHMIA
#34METHODS FOR TREATING CARDIOVASCULAR DISEASES
#35Methods of diagnosing post-operative complications using serum nitric oxide levels
#3613+/17+ BIN1 expression as a marker of cardiac disorders
#37Algorithm of NTproBNP and hand held ECG to detect arrhythmia in an elderly population
#38Assessment of Heart Failure and Arrhythmic Risk Stratification by Measuring Circulating Hu Proteins
#39METHOD OF DETERMINING RISK OF ARRHYTHMIA
#40MARKERS FOR ATRIAL FIBRILLATION (AF)
#41EVALUATING METHOD, EVALUATING APPARATUS, EVALUATING PROGRAM PRODUCT, EVALUATING SYSTEM, AND TERMINAL APPARATUS
#42DATA ANALYSIS OF CELLS UNDERGOING EXCITATION CONTRACTION COUPLING AS DETECTED ON REAL-TIME CELL ANALYSIS (RTCA) INSTRUMENTS
#43Methods for treating or predicting risk of a ventricular tachyarrhythmia event
#44Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
#45IN VITRO DIAGNOSTIC FOR MODEL-BASED THERAPY PLANNING
#46TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION
#47METHODS FOR MANAGING CARE OF PATIENTS PREDISPOSED TO PROGRESSIVE MITRAL VALVE DISEASES
#48TROPONIN AND BNP BASED DIAGNOSIS OF RISK PATIENTS AND CAUSE OF STROKE
#49Systems and methods for assessing data collected from an electrically active cell culture
#50Cardiotoxicity screening methods
#51METHODS OF TREATMENT OF CARDIAC ARRHYTHMIAS USING VANOXERINE AND MODIFICATION OF DIET
#52TROPONIN AND BNP BASED DIAGNOSIS OF RISK PATIENTS AND CAUSE OF STROKE
#53Body Fluid BIN1 as a Marker of Cardiac Health
#54TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION
#55Methods to identify modulators of RyR calcium channels
#56METHODS FOR DIAGNOSING CHRONIC VALVULAR DISEASE
#57Mid-regional pro-atrial natriuretic peptide (pro-ANP) for the identification of patients with atrial fibrillation with an onset of less than 48 hours ago
#58Diagnostic test for cardiomyopathy
#59Systems and methods for setting parameters of implantable medical devices using predictive marker data
#60Antibody that specifically binds to an epitope in the tureet region of a human Kir channel
#61RAP1A AS A MARKER FOR CARDIAC ARRHYTHMIA
#62SCN5A SPLICING FACTORS AND SPLICE VARIANTS FOR USE IN DIAGNOSTIC AND PROGNOSTIC METHODS
#63METHOD OF DETERMINING RISK OF ARRHYTHMIA
#64PDE1 AS A TARGET THERAPEUTIC IN HEART DISEASE
#65METHOD OF DETERMINING A PREDISPOSITION TO ATRIAL FIBRILLATION (AF) IN A SUBJECT
#66Data analysis of impedance-based cardiomyocyte-beating signals as detected on real-time cell analysis (RTCA) cardio instruments
#67Granin proteins as markers of heart disease
#68PRO-ENDOTHELIN-1 LEVELS FOR THE PREDICTION OF RISK OF TACHYARRHYTMIC EVENTS
#69Predicting atrial fibrillation recurrence by protease and protease inhibitor profiling
#70DIAGNOSIS AND TREATMENT OF CARDIAC DISORDERS
#71MARKER FOR ARRHYTHMIA RISK
#72NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2)
#73IDENTIFYING PATIENTS AT RISK FOR LIFE THREATENING ARRHYTHMIAS
#74Diagnostic test for cardiomyopathy
#75Animal Model With Induced Arrhythmia
#76Method of in vivo screening for cardiac toxic agents using teleost
#77CELLS AND ASSAYS FOR USE IN DETECTING LONG QT SYNDROME
#78MARKER FOR ARRHYTHMIA RISK
#79VOLTAGE-GATED ION CHANNEL MUTANTS FOR USE IN IDENTIFYING ION CHANNEL MODULATING COMPOUNDS
#80METHODS FOR IDENTIFYING AGENTS THAT TARGET LEAKS IN RYANODINE RECEPTORS
#81RYR2 MUTATIONS
#82B-Blocker Pharmacogenetics in Heart Failure
#83Treatment of patients with dysfunctional cardiac sodium channels
#84Method for predicting onset/risk of atrial fibrillation (AF)
#85Muscle Relaxtion Accelerator and Therapeutic Agent for Muscular Tissue Diseases Such as Muscle Relaxation Failure
#86Compositions and methods for modulating connexin hemichannels
#87Methods for screening compounds for proarrhythmic risk and antiarrhythmic efficacy
#88CaMKII/calcium channel phosphorylation-related compositions and methods
#89Identifying patients at risk for life threatening arrhythmias
#90Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
#91Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
#92Methods for identifying patients at risk for life threatening arrhythmias